Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
Genre
Journal ArticleDate
2017-12-01Author
Pizzuti, LMarchetti, P
Natoli, C
Gamucci, T
Santini, D
Scinto, AF
Iezzi, L
Mentuccia, L
D'Onofrio, L
Botticelli, A
Moscetti, L
Sperati, F
Botti, C
Ferranti, F
Buglioni, S
Sanguineti, G
Filippo, SD
Lauro, LD
Sergi, D
Catenaro, T
Tomao, S
Giordano, A
Maugeri-Saccà, M
Barba, M
Vici, P
Subject
AgedAndrostadienes
Antineoplastic Combined Chemotherapy Protocols
Biomarkers
Blood Glucose
Body Mass Index
Breast Neoplasms
Everolimus
Fasting
Female
Humans
Kaplan-Meier Estimate
Middle Aged
Prognosis
Treatment Outcome
Permanent link to this record
http://hdl.handle.net/20.500.12613/5111
Metadata
Show full item recordDOI
10.1038/s41598-017-10061-2Abstract
© 2017 The Author(s). Evidence on everolimus in breast cancer has placed hyperglycemia among the most common high grade adverse events. Anthropometrics and biomarkers of glucose metabolism were investigated in a observational study of 102 postmenopausal, HR + HER2- metastatic breast cancer patients treated with everolimus-exemestane in first and subsequent lines. Best overall response (BR) and clinical benefit rate (CBR) were assessed across subgroups defined upon fasting glucose (FG) and body mass index (BMI). Survival was estimated by Kaplan-Meier method and log-rank test. Survival predictors were tested in Cox models. Median follow up was 12.4 months (1.0-41.0). The overall cohort showed increasing levels of FG and decreasing BMI (p < 0.001). Lower FG fasting glucose at BR was more commonly associated with C/PR or SD compared with PD (p < 0.001). We also observed a somewhat higher BMI associated with better response (p = 0.052). More patients in the lowest FG category achieved clinical benefit compared to the highest (p < 0.001), while no relevant differences emerged for BMI. Fasting glucose at re-assessment was also predictive of PFS (p = 0.037), as confirmed in models including BMI and line of therapy (p = 0.049). Treatment discontinuation was significantly associated with changes in FG (p = 0.014). Further research is warranted to corroborate these findings and clarify the underlying mechanisms.Citation to related work
Springer Science and Business Media LLCHas part
Scientific ReportsADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/5093